Overview
The fund invests in stocks of major companies from established markets that are included in the MSCI Europe ex Switzerland Index.
No investments in securities on the recommendation list for the exclusion of SVVK-ASIR (www.svvk-asir.ch) and controversial weapons.
The fund holds almost all stocks in the MSCI Europe ex Switzerland Index. Individual stocks are held in proportion to the free-float market capitalisation of the index.
Diversification is achieved via a mix of sectors and countries and thus offers the investor an optimised risk/return profile.
The investment objective is to generate a performance in line with that of the benchmark, keeping the tracking error below the maximum of 0.5% over a rolling period of 3 years.
The funds described herein are indexed to an MSCI index.
Benefits
Easy access to the European (ex Switzerland) equity market
Optimised risk/return profile thanks to a broad diversification across a range of sectors.
Provides access to the performance of the index with a single transaction.
The fund is transparent and cost-effective and is liquid under normal market conditions.
You do not pay any federal stamp duty.
Risks
Features
| Product category |
Equity Europe |
| Product domicile |
Switzerland
|
| Portfolio management |
UBS SA国际传谋 Switzerland AG, Zurich
|
| Fund management |
UBS Fund Management (Switzerland) AG
|
| Custodian bank |
UBS Switzerland AG, Zurich
|
| Day of inception |
October 2, 2015
|
| Currency of account |
EUR
|
| Close of financial year |
September 30
|
| SFDR Classification |
n.a.
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
0.01% p.a.
|
| Flat fee |
0.00% p.a.
|
| Management fee |
0.00% p.a.
|
| Total expense ratio (TER) |
0.01% p.a.
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI Europe ex Switzerland (net div. reinv.) in EUR
|
| Cut-Off Time |
14:00h(CET)
|
| Securities no. |
29535557
|
| ISIN |
CH0295355579
|
| Bloomberg Ticker |
UBSEEPI SW
|
Performance and Prices
Percentage growth
as of April 23, 2026| EUR(%) | CHF(%) | USD(%) | |
| YTD | 5.00 | 3.57 | 4.70 |
| 1M | |||
| 3M | |||
| 6M | |||
| 1Y | |||
| 2Y | 20.21 | 19.19 | 36.35 |
| 3Y | |||
| 5Y | 66.96 | 38.69 | 62.27 |
| ø p.a.5Y | 10.80 | 6.76 | 10.17 |
Current data
| Net asset value | 23.04.2026 | EUR 2,144.94 |
| High - last 12 months | 26.02.2026 | EUR 2,189.93 |
| Low - last 12 months | 24.04.2025 | EUR 1,771.50 |
| Assets of the unit class in mn | 23.04.2026 | EUR 71.70 |
| Total product assets in mn | 23.04.2026 | EUR 712.68 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 31.03.2026 | 10.38% | 12.58% |
| Sharpe Ratio | 31.03.2026 | 0.71 | 0.65 |
| Risk Free Rate | 31.03.2026 | 2.75% | 1.89% |
Structures
By detailed securities (in %, as of February 27, 2026)*
|
|
|
| UBS Lux Institutional Fund - Equities Europe EX UK EX Switzerland Pass | 73.22 |
| UBS (CH) Institutional Fund - Equities UK Index NSL | 26.74 |
| NMC Health PLC | 0.00 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
|||
| Prospectus |
|
|
||
| Key Information Document |
|
|
|
|
| Past performance |
|
|
|
|
| Previous performance scenario |
|
|
|
|
|
Document type
|
Document Language
|
|
| Annual report |
|
|
| Semi-annual report |
|
|